Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Testimonials

Scientific discussions, flexibility and transparency, key to making our collaboration successful

We value our strong relationship with Syngene to support C4 Therapeutics’ research efforts across chemistry and biology to advance targeted protein degradation science. The scientific discussions, flexibility, and transparency between the teams have been key to making our collaboration successful.
Chris Nasveschuk
Senior Vice President, Chemistry, C4 Therapeutics

We look forward to continued successes from this collaboration

Over the past 25 years, we’ve seen a strong foundational partnership with Syngene flourish into a tremendous opportunity to expand our global R&D efforts in India, as the country provides a significant number of highly skilled and specialized talent in key areas of focus for Bristol Myers Squibb. We look forward to continued successes from this collaboration as we expand our local research and development engine.
Michael Ellis
Senior Vice President, Head, Small Molecule Drug Discovery, Bristol Myers Squibb

Syngene scientists named as inventors of this new production method

Syngene streamlined the production process of Panbela’s pancreatic cancer drug, SBP-101 while ensuring high chiral purity of 98% during GMP manufacturing. In recognition of the successful development of SBP-101 short synthesis by Syngene scientists, Panbela filed a US patent application naming Syngene scientists as the inventors of this new production method for SBP-101. This project undoubtedly brings to the fore, Syngene’s expertise and dedication in production processes for our investigational new product.

To know more about the work we did for Panbela, read Case Study
Thomas X. Neenan PhD
Chief Scientific Officer, Panbela Therapeutics Inc.

Pleased with the success of our long-standing collaboration

Amgen is pleased with the success of our long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials. We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.

To know more about our collaboration with Amgen, read Press Release
Margret Chu-Moyer, Ph.D
Vice President of Research and Head of Chemistry, Characterization & Technology, Amgen

Congratulations for a successful partnership

As we celebrate LUMAKRAS’ Prix Galien, I want to congratulate the Syngene Amgen Research Center (SARC) and Syngene for their partnership in developing this product through a number of compounds, impurities, standards, peak markers, starting material, and advanced intermediates.
Athimoolam Arunachalampillai
Amgen Leader for SARC -Process Development

Outstanding quality of work, excellent professionalism, dedication

As a pioneer in stem cell research and treatment in Malaysia, Cytopeutics Sdn. Bhd. has worked extensively with Syngene on multiple preclinical projects such as safety (toxicity and tumorigenicity) and proof-of-concept studies for our new investigational product. We were consistently impressed with how efficiently the studies were initiated and progressed, within the stipulated timeline, despite the incredibly tight schedule and budget. We are extremely pleased with Syngene’s outstanding quality of work, excellent professionalism, and the high level of dedication of each team member to our studies. With Syngene’s help, we could complete our preclinical studies in time to support our clinical trials and product registration requirements. We look forward to working together again.

To know more about the work we did for Cytopeutics, read Case Study
Dr. Chin Sze Piaw
Clinical and Research Advisor, Cytopeutics Sdn. Bhd., Malaysia

Thank you, and congratulations, Syngene

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for our human insulin. Thank you, and congratulations to the entire Syngene team for this successful application with European Medicines Agency (EMA).
Beena Uchil, Ph.D
Director, Product Development, Capstone Development Services Co, LLC

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details